Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable

Affiliations

• ¹ Cardiology Unit, Department of Medicine Solna, Karolinska Institute & Karolinska University Hospital, Stockholm, Sweden.
• ² Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomedica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
• ³ Department of Cardiovascular and Metabolic Diseases, IRCCS MultiMedica, Sesto San Giovanni, Italy.
• ⁴ Novo Nordisk A/S, Søborg, Denmark.
• ⁵ Department of Medicine, University of Padova, Padova, Italy.
• ⁶ Baylor College of Medicine, Houston, Texas, USA.
• ⁷ Campbell University College of Pharmacy and Health Sciences, Cary, North Carolina, USA.
• ⁸ Boehringer Ingelheim International, Pharma GmbH & Co. KG, Ingelheim, Germany.
• ⁹ Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
• ¹⁰ Diabetes Research Centre, Leicester, UK.
• ¹¹ AstraZeneca, Gothenburg, Sweden.
• ¹² Brigham and Women's Hospital, Boston, Massachusetts, USA.
• ¹³ Department of Medicine, K2, Karolinska Institute, Stockholm, Sweden.
• ¹⁴ Division of Diabetes, Nutrition, and Metabolic Disorders, Division of Clinical Pharmacology, CHU de Liège, University of Liège, Liège, Belgium.
• ¹⁵ Forschergruppe Diabetes eV at Munich Helmholtz Centre, Munich, Germany.
• ¹⁶ Department of Public Health, University of Helsinki, Helsinki, Finland.
• ¹⁷ Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.
• ¹⁸ Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
• ¹⁹ Inserm, Centre d'Investigations Cliniques- 1433, and Inserm U1116, CHRU, Nancy, France.
• ²⁰ Université de Lorraine, Nancy, France.
• ²¹ F-CRIN INI-CRCT, Nancy, France.